UXI Stock Overview
A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Cyclacel Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.46 |
| 52 Week High | US$2.38 |
| 52 Week Low | US$1.35 |
| Beta | 0.59 |
| 11 Month Change | -18.44% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -23.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| UXI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.9% | 1.2% | 0.8% |
| 1Y | n/a | -16.0% | 6.1% |
Return vs Industry: Insufficient data to determine how UXI performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how UXI performed against the German Market.
Price Volatility
| UXI volatility | |
|---|---|
| UXI Average Weekly Movement | 18.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: UXI's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine UXI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Spiro Rombotis | www.cyclacel.com |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.
Cyclacel Pharmaceuticals, Inc. Fundamentals Summary
| UXI fundamental statistics | |
|---|---|
| Market cap | €2.21m |
| Earnings (TTM) | -€18.36m |
| Revenue (TTM) | €415.24k |
5.3x
P/S Ratio-0.1x
P/E RatioIs UXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UXI income statement (TTM) | |
|---|---|
| Revenue | US$449.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$449.00k |
| Other Expenses | US$20.30m |
| Earnings | -US$19.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,420.49% |
| Debt/Equity Ratio | 0% |
How did UXI perform over the long term?
See historical performance and comparison